Drugs / AG-80308
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05372107 | Jun → Nov 2022 | dry eye syndrome | Allgenesis Biotherapeutics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-19 | Allgenesis Biotherapeutics Inc. | Results Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients allgenesis.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-19 | Allgenesis Biotherapeutics Inc. | Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients allgenesis.com ↗ |
| 2022-06-20 | Allgenesis Biotherapeutics Inc. | Allgenesis Announces First Patient Dosed in the U.S. for the Phase 1b trial Evaluating AG-80308 for the Treatment of Dry Eye Disease allgenesis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-80308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05372107 ↗ |
| Route | Topical | “topical AG-80308” NCT05372107 ↗ |